Ragifilimab

CAS No. 2207590-51-8

Ragifilimab( —— )

Catalog No. M36831 CAS No. 2207590-51-8

Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 211 Get Quote
5MG 330 Get Quote
10MG 543 Get Quote
25MG 845 Get Quote
50MG 1150 Get Quote
100MG 1521 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ragifilimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.
  • Description
    Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2207590-51-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hernandez-Guerrero T, et al: Not Ready for Prime Time. Clin Cancer Res. 2022 Sep 15;28(18):3905-3907.?
molnova catalog
related products
  • Adalimumab

    Adalimumab anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

  • Physcion 8-O-β-D-glu...

    Physcion 8-O-β-D-glucopyranoside has anti-inflammatory and anti-cancer activities. Physcion 8-O-β-D-glucopyranoside can be used in studies about common malignancy cancer.

  • Thalidomide

    Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.